Russell Investments Group Ltd. Buys 16,874 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Russell Investments Group Ltd. increased its stake in Blueprint Medicines Co. (NASDAQ:BPMC) by 15.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,902 shares of the biotechnology company’s stock after purchasing an additional 16,874 shares during the period. Russell Investments Group Ltd. owned 0.20% of Blueprint Medicines worth $10,981,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Empirical Asset Management LLC acquired a new stake in shares of Blueprint Medicines in the 4th quarter valued at $2,348,000. Stephens Inc. AR acquired a new stake in Blueprint Medicines in the fourth quarter worth about $321,000. Bank of New York Mellon Corp raised its holdings in Blueprint Medicines by 2.4% during the 4th quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company’s stock worth $26,465,000 after purchasing an additional 7,101 shares during the last quarter. KBC Group NV lifted its position in Blueprint Medicines by 63.9% during the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 1,023 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Blueprint Medicines in the 4th quarter valued at about $21,104,000.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BPMC. Piper Sandler boosted their price target on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Needham & Company LLC reissued a “buy” rating and issued a $133.00 price target on shares of Blueprint Medicines in a research note on Tuesday. JPMorgan Chase & Co. raised their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Finally, Scotiabank started coverage on Blueprint Medicines in a report on Friday, March 7th. They set a “sector outperform” rating and a $150.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Blueprint Medicines has an average rating of “Moderate Buy” and a consensus price target of $124.95.

Blueprint Medicines Stock Performance

BPMC opened at $80.84 on Friday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The company has a market capitalization of $5.17 billion, a price-to-earnings ratio of -74.85 and a beta of 0.75. The business’s 50-day moving average price is $90.91 and its two-hundred day moving average price is $93.51. Blueprint Medicines Co. has a 1 year low of $73.04 and a 1 year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Equities analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insider Transactions at Blueprint Medicines

In other Blueprint Medicines news, CEO Kate Haviland sold 1,446 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the sale, the chief executive officer now directly owns 149,378 shares of the company’s stock, valued at $16,467,430.72. The trade was a 0.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Christina Rossi sold 2,274 shares of the firm’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the transaction, the chief operating officer now owns 69,266 shares of the company’s stock, valued at $6,581,655.32. The trade was a 3.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 31,608 shares of company stock valued at $3,319,587 over the last 90 days. 4.21% of the stock is owned by corporate insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.